ClinicalTrials.gg
CompletedNCT06256107VR in MNDUpdated Feb 13, 2024

Virtual Reality in Motor Neurone Disease

An interventional study of Virtual Reality Headset in Motor Neuron Disease, sponsored by Lancashire Teaching Hospitals NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Lancashire Teaching Hospitals NHS Foundation Trust · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2021, registered Feb 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Motor Neurone Disease (MND) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication. The purpose of this study is to establish if Virtual Reality is useful for people with MND and if it helps improve their well being.

Read the detailed description

Motor Neurone Disease (MND) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication.

As people become increasingly immobile, they become restricted in their ability to perform activities of daily living, access the outdoors, participate in preferred occupational roles or engage in leisure activities. Consequently, there is a deterioration in their ability to experience well being and have quality of life. There is also a significant carer burden as the carer spends long hours in the day looking after the person. The average disease trajectory lasts between 3-5 years, followed by death. More recently, the use of Virtual Reality (VR) technology is being recognised in the field of health. This technology uses the interactions between an individual and a computer generated environment to stimulate different sensory modalities such as visual and auditory. The technology can be accessed commonly using head mounted goggles or head sets. The entertaining or stimulating effect of VR is useful in redirecting the person's attention away from the distressing experiences, such as pain and anxiety. The purpose of this study is to establish if VR is useful for people with MND and if it helps improve their well being.

02

Conditions studied

  • Motor Neuron Disease

Browse trials for

03

In context

Motor Neuron Disease

203 studies on the registry are indexed under Motor Neuron Disease; 61 are open to participants now.

This study's enrollment of 6 is below the median of 30 across 104 interventional studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

Lancashire Teaching Hospitals NHS Foundation Trust is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of MND
  2. Sufficient cognitive ability to understand instructions with regards using the VR kit (ECAS score - minimum 100/136)
  3. Has sufficient motor ability/dexterity to use the kit or a carer who will be able to assist with the use of the kit.
  4. Can tolerate light and have sufficient head control to wear the head set.
  5. English speaking

Exclusion criteria

Exclusion Criteria:

  1. Poor cognition - inability to understand instructions regarding the use of VR (Total ECAS Score \<100/136)
  2. Unable to tolerate light/unable to wear the head set
  3. Light sensitive epilepsy, severe vertigo or dizziness.
  4. Non English speaking
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Intervention

    The intervention period will last 4 weeks where participants will be required to use the VR set and document the time of use in a daily diary

    Device: Virtual Reality Headset

Interventions

  • DeviceVirtual Reality Headset

    Virtual Reality Headset

06

What researchers measure

Primary outcomes

  1. Edinburgh Mental Well being Scale

    Quality of Life (Scale 0-10 higher being better)

    Time frame: 4 weeks

Secondary outcomes

  1. ECAS (Edinburgh Cognition Assessment Scale)

    Cognition measure scale varied per question (Scale 0-8, 0-10, 0-12 higher being better)

    Time frame: 4 weeks

  2. PHQ-9

    scale for depression (Scale 0-27 - higher being worse)

    Time frame: 4 weeks

  3. GAD-7

    scale for anxiety (Scale 0-3 where higher is worse outcome)

    Time frame: 4 weeks

  4. ALS-FRS

    test of function (Yes or No - ability to perform function)

    Time frame: 4 weeks

07

Study locations

1 site
  • Lancashire Teaching Hospitals NHS Foundation Trust
    Preston, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No individual participant data will be shared

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06256107
Lead sponsor
Lancashire Teaching Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Jan 13, 2021
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update
Feb 13, 2024

Study contacts

Malabika Ghosh, PhD
principal investigator · Lancashire Teaching Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion